1887

Abstract

A nonapeptide (16L1) was derived from the human papillomavirus type 16 (HPV-16) major capsid protein and tested for detection of potential cross-reactive serum IgG and cervical IgA antibodies in low- and high-risk HPV-associated low-grade squamous intraepithelial lesions (LSIL) and cervical cancer patients by ELISA. The IgG response was similar in women with low-risk HPV-associated LSIL and controls (=0·1). In contrast, more than 90 % of patients with high-risk HPV-associated LSIL were seropositive. Although tumours from cancer patients were all positive for the presence of high-risk HPV DNA, the level of seropositivity decreased significantly in this group (<0·0001). Cervical IgA antibodies were also detected in a significantly high proportion of women with high-risk HPV-associated LSIL compared with controls. However, the proportion of IgA-positive patients was lower than the proportion of IgG seropositives. In conclusion, the 16L1 peptide appears to be a high-risk type-common epitope that induces cross-reactive antibodies in high-risk, but not low-risk, HPV-associated LSIL patients, allowing differentiation of high- and low-risk infected women at this stage of infection.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.80077-0
2004-09-01
2021-01-26
Loading full text...

Full text loading...

/deliver/fulltext/jgv/85/9/vir852643.html?itemId=/content/journal/jgv/10.1099/vir.0.80077-0&mimeType=html&fmt=ahah

References

  1. Af Geijersstam V., Kibur M., Wang Z., Koskela P., Pukkala E., Schiller J., Lehtinen M., Dillner J. 1998; Stability over time of serum antibody levels to human papillomavirus type 16. J Infect Dis 177:1710–1714 [CrossRef]
    [Google Scholar]
  2. Andersson-Ellstrom A., Dillner J., Hagmar B., Schiller J., Sapp M., Forssman L., Milsom I. 1996; Comparison of development of serum antibodies to HPV16 and HPV33 and acquisition of cervical HPV DNA among sexually experienced and virginal young girls. A longitudinal cohort study. Sex Transm Dis 23:234–238 [CrossRef]
    [Google Scholar]
  3. Bosch F. X., Manos M. M., Muñoz N. 7 other authors 1995; Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst 87:796–802 [CrossRef]
    [Google Scholar]
  4. Calderon-Aranda E. S., Selisko B., York E. J., Gurrola G. B., Stewart J. M., Possani L. D. 1999; Mapping of an epitope recognized by a neutralizing monoclonal antibody specific to toxin Cn2 from the scorpion Centruroides noxius , using discontinuous synthetic peptides. Eur J Biochem 264:746–755 [CrossRef]
    [Google Scholar]
  5. Carter J. J., Koutsky L. A., Hughes J. P., Lee S. K., Kuypers J., Kiviat N., Galloway D. A. 2000; Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 181:1911–1919 [CrossRef]
    [Google Scholar]
  6. Cason J., Kambo P. K., Best J. M., McCance D. J. 1992; Detection of antibodies to a linear epitope on the major coat protein (L1) of human papillomavirus type-16 (HPV-16) in sera from patients with cervical intraepithelial neoplasia and children. Int J Cancer 50:349–355 [CrossRef]
    [Google Scholar]
  7. Chen X. S., Garcea R. L., Goldberg I., Casini G., Harrison S. C. 2000; Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell 5:557–567 [CrossRef]
    [Google Scholar]
  8. Christensen N. D., Kirnbauer R., Schiller J. T., Ghim S. J., Schlegel R., Jenson A. B., Kreider J. W. 1994; Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes. Virology 205:329–335 [CrossRef]
    [Google Scholar]
  9. Christensen N. D., Dillner J., Eklund C., Carter J. J., Wipf G. C., Reed C. A., Cladel N. M., Galloway D. A. 1996; Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology 223:174–184 [CrossRef]
    [Google Scholar]
  10. Dillner J., Dillner L., Utter G., Eklund C., Rotola A., Costa S., DiLuca D. 1990; Mapping of linear epitopes of human papillomavirus type 16: the L1 and L2 open reading frames. Int J Cancer 45:529–535 [CrossRef]
    [Google Scholar]
  11. Dillner J., Wiklund F., Lenner P., Eklund C., Fredriksson-Shanazarian V., Schiller J. T., Hibma M., Hallmans G., Stendahl U. 1995; Antibodies against linear and conformational epitopes of human papillomavirus type 16 that independently associate with incident cervical cancer. Int J Cancer 60:377–382
    [Google Scholar]
  12. Gausepohl H., Boulin C., Kraft M., Frank R. W. 1992; Automated multiple peptide synthesis. Pept Res 5:315–320
    [Google Scholar]
  13. Giuliano A. R., Papenfuss M., Schneider A., Nour M., Hatch K. 1999; Risk factors for high-risk type human papillomavirus infection among Mexican–American women. Cancer Epidemiol Biomarkers Prev 8:615–620
    [Google Scholar]
  14. Heino P., Skyldberg B., Lehtinen M., Rantala I., Hagmar B., Kreider J. W., Kirnbauer R., Dillner J. 1995; Human papillomavirus type 16 capsids expose multiple type-restricted and type-common antigenic epitopes. J Gen Virol 76:1141–1153 [CrossRef]
    [Google Scholar]
  15. Karlsen F., Kalantari M., Jenkins A., Pettersen E., Kristensen G., Holm R., Johansson B., Hagmar B. 1996; Use of multiple PCR primer sets for optimal detection of human papillomavirus. J Clin Microbiol 34:2095–2100
    [Google Scholar]
  16. Kaye J. N., Cason J., Pakarian F. B., Jewers R. J., Kell B., Bible J., Raju K. S., Best J. M. 1994; Viral load as a determinant for transmission of human papillomavirus type 16 from mother to child. J Med Virol 44:415–421 [CrossRef]
    [Google Scholar]
  17. Kirnbauer R., Taub J., Greenstone H., Roden R., Durst M., Gissmann L., Lowy D. R., Schiller J. T. 1993; Efficient self-assembly of human papillomavirus type 16 L1 and L1–L2 into virus-like particles. J Virol 67:6929–6936
    [Google Scholar]
  18. Kirnbauer R., Hubbert N. L., Wheeler C. M., Becker T. M., Lowy D. R., Schiller J. T. 1994; A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst 86:494–499 [CrossRef]
    [Google Scholar]
  19. LeCann P., Chabaud M., Leboulleux D. 7 other authors 1995; Detection of antibodies to L1, L2, and E4 proteins of human papillomavirus types 6, 11, and 16 by ELISA using synthetic peptides. J Med Virol 45:410–414 [CrossRef]
    [Google Scholar]
  20. Manos M. M., Ting Y., Wright D. K., Lewis A. J., Broker T. R., Wolinsky S. M. 1989; Use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. Cancer Cells 7:209–214
    [Google Scholar]
  21. Melsheimer P., Kaul S., Dobeck S., Bastert G. 2003; Immunocytochemical detection of HPV high-risk type L1 capsid proteins in LSIL and HSIL as compared with detection of HPV L1 DNA. Acta Cytol 47:124–128 [CrossRef]
    [Google Scholar]
  22. Monroy-Garcia A., Weiss-Steider B., Hernandez-Montes J. 10 other authors 2002; Identification of two homologous antigenic peptides derived from L1 HPV-16 and -18 proteins specific for the HLA-B*3901 allele. Arch Virol 147:1933–1942 [CrossRef]
    [Google Scholar]
  23. Parkin D. M., Pisani P., Ferlay J. 1999; Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 80:827–841 [CrossRef]
    [Google Scholar]
  24. Rocha-Zavaleta L., Pereira-Suarez A. L., Yescas G., Cruz-Mimiaga R. M., Garcia-Carranca A., Cruz-Talonia F. 2003; Mucosal IgG and IgA responses to human papillomavirus type 16 capsid proteins in HPV16-infected women without visible pathology. Viral Immunol 16:159–168 [CrossRef]
    [Google Scholar]
  25. Saiki R. A., Bugawan T. L., Horn G. T., Mullis K. B., Erlich H. A. 1986; Analysis of enzymatically amplified β -globin and HLA DQ alpha DNA with allele specific oligonucleotide probes. Nature 324:163–166 [CrossRef]
    [Google Scholar]
  26. Shah K. V., Viscidi R. P., Alberg A. J., Helzlsouer K. J., Comstock G. W. 1997; Antibodies to human papillomavirus 16 and subsequent in situ or invasive cancer of the cervix. Cancer Epidemiol Biomarkers Prev 6:233–237
    [Google Scholar]
  27. Sharma B. K., Ray A., Murthy N. S. 1996; Prevalence of serum antibodies to synthetic peptides to HPV16 epitopes among Indian women with cervical neoplasia. Eur J Cancer 32A:872–876
    [Google Scholar]
  28. Stoler M. H., Rhodes C. R., Whitbeck A., Wolinsky S. M., Chow L. T., Broker T. R. 1992; Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Hum Pathol 23:117–128 [CrossRef]
    [Google Scholar]
  29. Uray K., Price M. R., Majer Z., Vass E., Hollosi M., Hudecz F. 2003; Identification and solution conformation of multiple epitopes recognized by a MUC2 mucin-specific monoclonal antibody. Arch Biochem Biophys 410:254–260 [CrossRef]
    [Google Scholar]
  30. Walboomers J. M. M., Meijer C. J. L. M. 1997; Do HPV-negative cervical carcinomas exist?. J Pathol 181:253–254 [CrossRef]
    [Google Scholar]
  31. Walboomers J. M. M., Jacobs M. V., Manos M. M. 1999; Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12–19 [CrossRef]
    [Google Scholar]
  32. Wang Z., Hansson B. G., Forslund O., Dillner L., Sapp M., Schiller J. T., Bjerre B., Dillner J. 1996; Cervical mucus antibodies against human papillomavirus type 16, 18, and 33 capsids in relation to presence of viral DNA. J Clin Microbiol 34:3056–3062
    [Google Scholar]
  33. Wang Z., Christensen N., Schiller J. T., Dillner J. 1997; A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera. J Gen Virol 78:2209–2215
    [Google Scholar]
  34. White W. I., Wilson S. D., Palmer-Hill F. J. 8 other authors 1999; Characterization of a major neutralizing epitope on human papillomavirus type 16 L1. J Virol 73:4882–4889
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.80077-0
Loading
/content/journal/jgv/10.1099/vir.0.80077-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error